Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset.

G. Fond, , L. Boyer, M. Favez, L. Brunel, B. Aouizerate, F. Berna, D. Capdevielle, I. Chereau, J. M. Dorey, C. Dubertret, Dubreucq, C. Faget, F. Gabayet, H. Laouamri, C. Lancon, Y. Le Strat, D. Misdrahi, R. Rey, C. Passerieux, A. Schandrin, F. Schurhoff, A. M. Tronche, M. Urbach, P. Vidalhet, P. M. Llorca, A. Pelissolo
Psychopharmacology. 2015-12-03; 233(4): 571-578
DOI: 10.1007/s00213-015-4167-8

PubMed
Read on PubMed



Fond G(1)(2)(3), Boyer L(4)(5)(6), Favez M(7)(6), Brunel L(4)(7)(6), Aouizerate
B(4)(8)(6)(9), Berna F(4)(10)(6), Capdevielle D(4)(11)(6), Chereau I(4)(12)(6),
Dorey JM(4)(13)(6), Dubertret C(4)(14)(6), Dubreucq(4)(15)(6), Faget
C(4)(16)(6), Gabayet F(4)(15)(6), Laouamri H(4)(6), Lancon C(4)(16)(6), Le Strat
Y(4)(14)(6), Misdrahi D(4)(8)(6)(17), Rey R(4)(13)(6), Passerieux C(4)(18)(6),
Schandrin A(4)(11)(6), Schurhoff F(4)(7)(6), Tronche AM(4)(12)(6), Urbach
M(4)(18)(6), Vidalhet P(10)(6), Llorca PM(4)(12)(6), Pelissolo A(4)(7)(6);
FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group.

Collaborators: Aouizerate B, Berna F, Blanc O, Brunel L, Bulzacka E, Capdevielle
D, Chereau-Boudet I, Chesnoy-Servanin G, Danion JM, D’Amato T, Deloge A, Delorme
C, Denizot H, De Pradier M, Dorey JM, Dubertret C, Dubreucq J, Faget C, Fluttaz
C, Fond G, Fonteneau S, Gabayet F, Giraud-Baro E, Hardy-Bayle MC, Lacelle D,
Lançon C, Laouamri H, Leboyer M, Le Gloahec T, Le Strat Y, Llorca PM, Metairie
E, Misdrahi D, Offerlin-Meyer I, Passerieux C, Peri P, Pires S, Portalier C, Rey
R, Roman C, Sebilleau M, Schandrin A, Schurhoff F, Tessier A, Tronche AM, Urbach
M, Vaillant F, Vehier A, Vidailhet P, Vilain J, Vilà E, Yazbek H,
Zinetti-Bertschy A.

Author information:
(1)Fondation FondaMental, Créteil, France. .
(2)INSERM U955, équipe de psychiatrie translationnelle, Créteil, France,
Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, 40 rue de Mesly, F-94010, Créteil, France.
.
(3)Bordeaux Sleep Clinique, Pellegrin University Hospital, USR CNRS 3413 SANPSY,
Research Unit, Bordeaux University, 33000, Bordeaux, France.
.
(4)Fondation FondaMental, Créteil, France.
(5)Pôle Psychiatrie Universitaire, CHU Sainte-Marguerite, F-13274, Marseille
cedex 09, France.
(6)Bordeaux Sleep Clinique, Pellegrin University Hospital, USR CNRS 3413 SANPSY,
Research Unit, Bordeaux University, 33000, Bordeaux, France.
(7)INSERM U955, équipe de psychiatrie translationnelle, Créteil, France,
Université Paris-Est Créteil, DHU Pe-PSY, Pôle de Psychiatrie des Hôpitaux
Universitaires H Mondor, 40 rue de Mesly, F-94010, Créteil, France.
(8)Centre Hospitalier Charles Perrens, Université de Bordeaux, F-33076,
Bordeaux, France.
(9)Inserm, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale,
U862, F-33000, Bordeaux, France.
(10)INSERM U1114, Fédération de Médecine Translationnelle de Strasbourg,
Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg,
France.
(11)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France.
(12)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69 63003,
Clermont-Ferrand Cedex 1, France.
(13)Université Claude Bernard Lyon 1/Centre Hospitalier Le Vinatier, Pole Est BP
300 39-95 bd, Pinel – 69678, BRON Cedex, France.
(14)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, Inserm
U894, Université Paris Diderot, Faculté de médecine, Sorbonne, Paris Cité,
France.
(15)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France.
(16)Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle Universitaire de
Psychiatrie, Marseille, France.
(17)CNRS UMR 5287-INCIA, Bordeaux, France.
(18)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, UFR des
Sciences de la Santé Simone Veil, Université Versailles Saint-Quentin en
Yvelines, Versailles, France.

Comment in
Psychopharmacology (Berl). 2016 Jun;233(12):2419-20.
Psychopharmacology (Berl). 2016 Jun;233(12):2421-3.

INTRODUCTION: The primary objective of this study was to determine if
second-generation antipsychotic (SGA) administration was associated with lower
aggressiveness scores compared to first-generation (FGA) in schizophrenia (SZ).
The secondary objective was to determine if antidepressants, mood stabilizers,
and benzodiazepines administration were respectively associated with lower
aggressiveness scores compared to patients who were not administered these
medications.
METHODS: Three hundred thirty-one patients with schizophrenia (N = 255) or
schizoaffective disorder (N = 76) (mean age = 32.5 years, 75.5 % male gender)
were systematically included in the network of FondaMental Expert Center for
Schizophrenia and assessed with the structured clinical interview for DSM-IV
Axis I disorders and validated scales for psychotic symptomatology, insight, and
compliance. Aggressiveness was measured by the Buss-Perry Aggression
Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded.
RESULTS: Patients who received SGA had lower BPAQ scores than patients who did
not (p = 0.01). More specifically, these patients had lower physical and verbal
aggression scores. On the contrary, patients who received benzodiazepines had
higher BPAQ scores than patients who did not (p = 0.04). No significant
difference was found between BPAQ scores of patients respectively being
administered mood stabilizers (including valproate), antidepressant, and the
patients who were not. These results were found independently of
socio-demographical variables, psychotic symptomatology, insight, compliance
into treatment, daily-administered antipsychotic dose, the way of antipsychotic
administration (oral vs long acting), current alcohol disorder, and daily
cannabis consumption.
CONCLUSION: The results of the present study are in favor of the choice of SGA
in SZ patients with aggressiveness, but these results need further investigation
in longitudinal studies. Given the potent side effects of benzodiazepines
(especially dependency and cognitive impairment) and the results of the present
study, their long-term prescription is not recommended in patients with
schizophrenia and aggressive behavior.

DOI: 10.1007/s00213-015-4167-8
PMID: 26630993 [Indexed for MEDLINE]

Know more about